மருந்துகள் கனடா இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்துகள் கனடா இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்துகள் கனடா இன்க் Today - Breaking & Trending Today

Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease

Share this article
Share this article
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.
Ilaris, an interleukin-1 beta inhibitor, provides a new mode of treatment for this disease
which previously had limited options.
1,2
DORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris
®
(canakinumab) for the treatment of active Still s disease, including adult-onset Still s disease (AOSD)
1. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications ....

Julie Schneiderman , Derek Haaland , Andrea Marazzi , Novartis Pharmaceuticals Canada , Novartis Pharmaceuticals Canada Inc , Novartis Corporate Communications , Health Canada , Pharmaceuticals Canada , Systemic Juvenile Idiopathic Arthritis , Country Head , Novartis Pharmaceuticals , Periodic Fever Syndromes , Cryopyric Associated Periodic Syndrome , Pharmaceuticals Canada Inc , Clinical Risk Management , Adult Onset Still , Onset Still , Autoimmunity Reviews , Novartis Media Relations , ஜூலி ஸ்ச்சினெதெர்மன் , ஆண்ட்ரியா மராஸி , நோவர்த்திச் மருந்துகள் கனடா , நோவர்த்திச் மருந்துகள் கனடா இன்க் , நோவர்த்திச் பெருநிறுவன தகவல்தொடர்புகள் , ஆரோக்கியம் கனடா , மருந்துகள் கனடா ,

Novartis in Canada named a Top 50 Best Workplace™ in the country

Novartis in Canada named a Top 50 Best Workplace™ in the country
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Novartis Innovative Medicines Division Pharmaceuticals , Novartis Pharmaceuticals Canada Inc , Novartis Pharmaceuticals Canada , Great Place , Novartis Innovative Medicines Division , Christian Macher , Country President , Pharmaceuticals Canada Inc , Sandoz Canada , Pharmaceuticals Canada , Novartis Innovative Medicines Division , நோவர்த்திச் மருந்துகள் கனடா இன்க் , நோவர்த்திச் மருந்துகள் கனடா , நன்று இடம் , நாடு ப்ரெஸிடெஂட் , மருந்துகள் கனடா இன்க் , சாண்டோஸ் கனடா , மருந்துகள் கனடா ,

Canada to receive additional 2 million doses of AstraZeneca's COVID-19 vaccine

Canada to receive additional 2 million doses of AstraZeneca's COVID-19 vaccine
thesuburban.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thesuburban.com Daily Mail and Mail on Sunday newspapers.

Astrazeneca Chadox , Astrazeneca Canada Inc , Health Canada On , Serum Institute , Health Canada , Public Services , Verity Pharmaceuticals Canada Inc , Pharmaceuticals Canada Inc , ஆரோக்கியம் கனடா ஆன் , சீரம் நிறுவனம் , ஆரோக்கியம் கனடா , பொது சேவைகள் , உண்மை மருந்துகள் கனடா இன்க் , மருந்துகள் கனடா இன்க் ,

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Share this article

SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2
2,3
Zolgensma (onasemnogene abeparvovec) is approved for the treatment of pediatric SMA patients with 3 or fewer copies of the SMN2 gene, or infantile-onset SMA
1
Zolgensma is designed to address the genetic root cause of SMA by replacing the missing or defective SMN1 gene to halt disease progression
1
DORVAL, QC, Dec. 16, 2020 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Zolgensma
® (onasemnogene abeparvovec) an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 ( ....

City Of , United Kingdom , British Columbia , Nicolas Chrestian , Susi Vander Wyk , Julie Schneiderman , Hugh Mcmillan , Andrea Marazzi , Canadian Pharmaceutical Alliance , Novartis Pharmaceuticals Canada , National Organization For Rare Disorders , Novartis Pharmaceuticals Canada Inc , Health Canada , Centre Hospitalier , Pediatric Neurologist , Eastern Ontario , Paediatric Neurology , Enfant Soleil , Executive Director , Country Head , Novartis Pharmaceuticals , Quebec City , Gene Therapy , Pharmaceuticals Canada Inc , Novartis Gene , Gene Therapies ,